Chattem ephedra
This article was originally published in The Tan Sheet
Executive Summary
Roughly $2 mil. to $2.5 mil. in ephedra-containing Dexatrim remained on retail shelves as of March, although all such products "should be off shelves by May," Chattem tells investors April 3 at Banc of America Securities Consumer Conference. Chattanooga, Tenn.-based firm took $750,000 hit in Q1 to replace product with new formulation, execs add. Despite charge, first quarter revenue reached $58.4 mil., a 20.7% increase over year-ago period, attributable in part to growing Selsun Blue sales (1"The Tan Sheet" March 24, 2003, In Brief)...
You may also be interested in...
Chattem Icy Hot ads
Q3 launch of Icy Hot Back Patch will be supported with $12 mil. TV, print ad campaign featuring Los Angeles Lakers basketball star Shaquille O'Neal; initiative is expected to spur topical analgesic sales growth in second half, President & COO Alec Taylor says during March 20 analysts call. Chattem has said the line extension could generate annual sales of $6 mil.-$8 mil. (1"The Tan Sheet" Jan. 27, 2003, p. 6). Firm's Q1 revenue jumps 20.7% to $58.4 mil., bolstered by 38% rise in Selsun Blue sales, along with double-digit gains by Icy Hot, pHisoderm, Garlique, Chattanooga, Tenn.-based firm reports. International revenues leap 89% in first quarter, "led by sales of Selsun Blue and the continuing strength of Gold Bond in Canada." Chattem's net income reached $4.6 mil. versus a loss of $6.5 mil. in year-ago period...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.